CORE-007: BIOSTATISTICS SHARED RESOURCE (BSR) PROJECT SUMMARY / ABSTRACT The Biostatistics Shared Resource (BSR) provides The Ohio State University Comprehensive Cancer Center (OSUCCC) investigators with a centralized resource for biostatistical expertise. The BSR is directed by Dr. Soledad Fernandez and the Associate Director is Dr. Kevin Coombes (TT). Statistical issues are addressed at all levels of investigation, from the design of experiments to the maintenance of data quality, and from conclusions based on formal hypothesis testing to important leads discovered by data exploration. In support of this objective, the Specific Aims of this resource are to: 1) collaborate with OSUCCC investigators in all aspects of biomedical research: design, implementation and discovery; 2) enable strong and consistent collaborations by providing a biostatistical ?navigator? to all OSUCCC programs and disease groups; and 3) provide biostatistical and methodological review of all cancer protocols submitted to the Clinical Scientific Review Committee (CSRC) and the Data Safety Monitoring Committee (DSMC), and to provide support to the Biospecimen Services Shared Resource and its Total Cancer Care protocol. Over the past five years, the BSR has increased its integration and collaborations with all OSUCCC programs. The main highlights of BSR activities during the last funding period include: 1) BSR biostatisticians supported 254 cancer-related papers and 14 of these had a journal impact factor >10. These metrics represent a 33% increase in number of publications since our last grant. 2) BSR members received support from 11 renewed and 3 new programmatic grants, including the first NCI-funded Thyroid Cancer SPORE and also 36 R01s. 3) BSR hired nine additional biostatisticians to support OSUCCC investigators, including Dr. Kevin Coombes (TT), former Director of the Bioinformatics Shared Resource at MD Anderson Cancer Center. Other recruits have enhanced our clinical trials expertise with Bayesian methodologies. 4) BSR implemented a new biostatistical navigator model to expand, improve and unify support to OSUCCC investigators while maintaining access to the wide breadth of expertise with other biostatisticians across different OSU colleges. 5) The BSR increased its interactions with the Disease Specific Research Groups DSRGs by assigning a dedicated biostatistician to each group. 6) BSR integrates support with other shared resources, such as Biomedical Informatics Shared Resource, Genomics Shared Resource, Pharmacoanalytical Shared Resource, Analytical Cytometry Shared Resource and Behavioral Measurement Shared Resource. 7) BSR members provided education and promoted the benefits of innovative designs for early phase clinical trials to OSUCCC investigators. The BSR leverages extensive institutional support, and seeks only 7.7% support from CCSG funds. The Biostatistics Shared Resource is part of the Quantitative Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-41
Application #
9221252
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications